Effectiveness of open-label donepezil treatment in patients with Alzheimer's disease discontinuing memantine monotherapy^*

References

• Wimo A, Winblad B, Jönsson L. An estimate of the total worldwide societal costs of dementia in 2005. Alzheimers Dement 2007;3: 81–91
   Google Scholar
• Ferri CP, Prince M, Brayne C, et al. Global prevalence of dementia: a Delphi consensus study. Lancet 2005;366:2112–17
   PubMed Web of Science ®Google Scholar
• Fratiglioni L, Launer LJ, Andersen K, et al. Incidence of dementia and major subtypes in Europe: a collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology 2000;54(11 Suppl 5):S10–15
   Google Scholar
• Hebert LE, Scherr PA, Bienias JL, et al. Alzheimer disease in the US population: prevalence estimates using the 2000 census. Arch Neurol 2003;60:1119–22
   PubMed Web of Science ®Google Scholar
• Rosler M, Anand R, Cicin-Sain A, et al. Efficacy and safety of rivastigmine in patients with Alzheimer’s disease: international randomised controlled trial. BMJ 1999;318:633–8
   Google Scholar
• Tariot PN, Solomon PR, Morris JC, et al. A 5-month, randomized, placebo-controlled trial of galantamine in AD. Neurology 2000;54:2269–76
   PubMed Web of Science ®Google Scholar
• Winblad B, Engedal K, Soininen H, et al. A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. Neurology 2001;57:489–95
   PubMed Web of Science ®Google Scholar
• Holmes C, Wilkinson D, Dean C, et al. The efficacy of donepezil in the treatment of neuropsychiatric symptoms in Alzheimer disease. Neurology 2004;63:214–19
   PubMed Web of Science ®Google Scholar
• Feldman H, Gauthier S, Hecker J, et al. A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer’s disease. Neurology 2001;57:613–20
   PubMed Web of Science ®Google Scholar
• Reisberg B, Doody R, Stoffler A, et al. Memantine in moderate-to-severe Alzheimer’s disease. N Engl J Med 2003;348:1333–41
   PubMed Web of Science ®Google Scholar
• Winblad B, Kilander L, Eriksson S, et al. Donepezil in patients with severe Alzheimer’s disease: double-blind, parallel-group, placebo-controlled study. Lancet 2006;367:1057–65
   PubMed Web of Science ®Google Scholar
• Bartus RT, Dean RL 3rd, Beer B, Lippa AS. The cholinergic hypothesis of geriatric memory dysfunction. Science 1982;217:408–14
   Google Scholar
• Francis PT. Glutamatergic systems in Alzheimer’s disease. Int J Geriatr Psychiatry 2003;18(Suppl 1):S15–21
   PubMedGoogle Scholar
• Johannsen P, Salmon E, Hampel H, et al. Assessing therapeutic efficacy in a progressive disease: a study of donepezil in Alzheimer’s disease. CNS Drugs 2006;20:311–25. Erratum in: CNS Drugs 2006;20: 866
   Google Scholar
• Klinger T, Ibach B, Schoenknecht P, et al. Effect of donepezil in patients with Alzheimer’s disease previously untreated or treated with memantine or nootropic agents in Germany: an observational study. Curr Med Res Opin 2005;21:723–32
   PubMed Web of Science ®Google Scholar
• Diagnostic and Statistical Manual of Mental Disorders. Fourth edition, Text revision. ed. Washington, DC: American Psychiatric Association; 2000
   Google Scholar
• McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology 1984;34:939–44
   PubMed Web of Science ®Google Scholar
• Folstein MF, Folstein SE, McHugh PR. ‘Mini-Mental State’: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189–98
   Google Scholar
• Cummings JL, Mega M, Gray K, et al. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 1994;44:2308–14
   PubMed Web of Science ®Google Scholar
• Guy W. ECDEU Assessment Manual for Psychopharmacology (Revised). US Department of Health, Education, and Welfare; Rockville, MD: NIMH; 1976:217–22
   Google Scholar
• Feldman H, Gauthier S, Hecker J, et al. Efficacy of donepezil on maintenance of activities of daily living in patients with moderate to severe Alzheimer’s disease and the effect on caregiver burden. J Am Geriatr Soc 2003;51:737–44. Erratum in: J Am Geriatr Soc. 2003;51: 1331
   Web of Science ®Google Scholar
• Wilkinson DG, Passmore AP, Bullock R, et al. A multinational, randomised, 12-week, comparative study of donepezil and rivastigmine in patients with mild to moderate Alzheimer’s disease. Int J Clin Pract 2002;56:441–6
   PubMed Web of Science ®Google Scholar
• Jones RW, Soininen H, Hager K, et al. A multinational, randomised, 12-week study comparing the effects of donepezil and galantamine in patients with mild to moderate Alzheimer’s disease. Int J Geriatr Psychiatry 2004;19:58–67
   PubMed Web of Science ®Google Scholar
• Boada-Rovira M, Brodaty H, Cras P, et al. Efficacy and safety of donepezil in patients with Alzheimer’s disease: results of a global, multinational, clinical experience study. Drugs Aging 2004;21:43–53
   Google Scholar
• Coen RF, Swanwick GR, O’Boyle CA, Coakley D. Behaviour disturbance and other predictors of carer burden in Alzheimer’s disease. Int J Geriatr Psychiatry 1997;12: 331–6
   Google Scholar
• Steele C, Rovner B, Chase GA, Folstein M. Psychiatric symptoms and nursing home placement of patients with Alzheimer’s disease. Am J Psychiatry 1990;147:1049–51
   PubMed Web of Science ®Google Scholar
• Winblad B, Brodaty H, Gauthier S, et al. Pharmacotherapy of Alzheimer’s disease: is there a need to redefine treatment success? Int J Geriatr Psychiatry 2001;16:653–66
   PubMed Web of Science ®Google Scholar
• Geldmacher DS, Frolich L, Doody RS, et al. Realistic expectations for treatment success in Alzheimer’s disease. J Nutr Health Aging 2006;10:417–29
   PubMed Web of Science ®Google Scholar
• Doody RS, Geldmacher DS, Gordon B, et al. Open-label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease. Arch Neurol 2001;58:427–33
   PubMed Web of Science ®Google Scholar
• Raskind MA, Peskind ER, Truyen L, et al. The cognitive benefits of galantamine are sustained for at least 36 months: a long-term extension trial. Arch Neurol 2004;61:252–6
   PubMed Web of Science ®Google Scholar
• Winblad B, Wimo A, Engedal K, et al. 3-year study of donepezil therapy in Alzheimer’s disease: effects of early and continuous therapy. Dement Geriatr Cogn Disord 2006;21:353–63
   PubMed Web of Science ®Google Scholar
• Black SE, Doody R, Li H, et al. Donepezil preserves cognition and global function in patients with severe Alzheimer disease. Neurology 2007;69:459–69
   PubMed Web of Science ®Google Scholar